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Figure. ATG16C1HM recipients have increased mortality after allo-HSCT with increased expression of activation/maturation molecules in recipient DCs. (A, B)
Lethally irradiated C57BL/6 wild-type or ATG16L1HM recipients were transplanted with B10.BR TCD BM cells with 2  106 B10.BR T cells. (A) Survival. (B) Histogram
overlays of activation/maturation molecules expression of recipient DCs. Recipient spleens were harvested on day 7 after allo-HSCT. Data are representative of two
independent experiments.***, P < 0.001.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S22eS26S24which is involved in T cell trafﬁcking to the intestines. This
correlated with signiﬁcantly increased numbers of inﬁl-
trating donor T cells in the intra-epithelial compartment of
the small intestines (P< 0.05). HM recipients had greater loss
of intestinal integrity as demonstrated by increased intesti-
nal permeability after oral FITC-dextran gavage (P < 0.01)
and increased bacterial colony growth from spleen and blood
(P < 0.05). To further assess the increased alloreactivity of
donor Tcells in HM recipients, we analyzed recipient-derived
dendritic cells (DC) in HM vs WT recipients and noted a)
increased numbers, b) increased expression of activation/
maturation molecules (CD40, CD80 and CD86; Figure B) by
ﬂow cytometry and transcriptome microarray and c)
increased alloactivation of donor T cells when tested in a
mixed lymphocyte reaction. In addition, we demonstrated
that in vitro culture of DCs with an autophagy-inducing drug
(resveratrol) resulted in decreased expression of activation/
maturation molecules (P < 0.001).
To determine if ATG16L1 deﬁciency in recipient DCs is suf-
ﬁcient, we performed experiments with CD11c-Cre/Atg16l1f/f
recipients (in which the ATG16L1 deﬁciency is restricted to
CD11c+ DC in the recipient) and found increased GVHD.
Finally, to assess whether ATG16L1 contributes to GVHD
through its role in autophagy, we treated allo-HSCT re-
cipients with an autophagy inhibitor (Lys05; 10 mg/kg i.p.,
days -3 to 30) and found signiﬁcantly increased GVHD.
In conclusion, these preclinical studies demonstrate that loss
of ATG16L1 expression in allo-HSCT recipients results in
increased activation/maturation of DC leading to increased
alloactivation of donor T cells and worse GVHD.
Based on these observations in mice we analyzed a cohort of
122 allo-HSCT patients, who had received an allograft from a
HLA-identical sibling and found that the presence of ATG16L1
SNPs either in donor or recipient resulted in increased
mortality, although only donor ATG16L1 SNP reached statis-
tical signiﬁcance in this small cohort (P ¼ 0.026).
Taken together, our results in mouse and man suggest that
ATG16L1 and autophagy are involved in the pathophysiology
of GVHD and raise the possibility that strategies to induce
autophagy could ameliorate GVHD.CIBMTR BEST ABSTRACT AWARDS FOR CLINICAL
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The Primary Immune Deﬁciency Treatment Consortium
(PIDTC) conducted a retrospective study of 240 SCID pa-
tients transplanted at 25 consortium centers from 2000-
2009. Patients with a diagnosis of typical SCID, as deﬁned
by recently published PIDTC consensus criteria, who un-
derwent allogeneic HCT were included after central review.
Leaky SCID and Omenn syndrome were excluded. Donors
included matched sibling (MSD), T-cell depleted (TCD)
mismatched related (MMRD), and unmodiﬁed other
related/unrelated donors (OD). Cell sources included bone
marrow (BM), peripheral blood (PB) and umbilical cord
blood (UCB) (See Table). The vast majority of MSD and TCD
MMRD HCT were performed without conditioning and the
rest were divided between those receiving immunosup-
pression (IS, no busulfan, thiotepa or melphalan), reduced
intensity (RIC, containing alkylating agents equivalent to
<12 mg/kg busulfan) and myeloablative conditioning (MAC,
equivalent to ¼ or >12 mg/kg busulfan). The overall 5-year
survival (OS) rate was 74% (178/240). Multivariate analysis
of OS revealed superior outcomes for MSD when compared
to TCD MMRD or unmodiﬁed OD grafts (Fig. 1A). However,
irrespective of the type of transplant administered, patients
age <3.5 months and patients of any age who were free of
infection at HCT, all had excellent OS, similar to MSD (OS
88-100%) (Fig. 1B-E). Thus, freedom from infection at HCT
had a central role in outcomes of non-MSD HCT for SCID.
Conditioning with RIC/MAC did not affect survival (Fig. 1F).
RIC/MAC also did not inﬂuence donor T cell engraftment in
MSD recipients, who had the lowest rate of 2nd transplant
(6.3%) despite lack of conditioning, nor in non-MSD re-
cipients (2nd transplant none/IS 23% vs. RIC/MAC 16%).
However, while 92% of all patients tested had normal T cell










Graft type BM 139 31 85 8 15
PB 58 1 53 0 4
UCB 43 0 0 0 43
Conditioning
regimen
None 120 21 87 6 6
IS 39 7 16 1 15
RIC 35 2 10 1 22
MAC 46 2 25 0 19
Figure 1.(CD3+ >1000/ul) was signiﬁcantly enhanced by RIC/MAC.
Donor type and genetic subtype of SCID also inﬂuenced T-
cell recovery following non-MSD HCT. Humoral immunity
was consistently achieved post MSD HCT despite lack of
conditioning; for patients who received non-MSD HCT, IVIG
independence was much more likely in those who received
RIC/MAC (84.6% vs. 28.2%, p<0.001). Our study indicates
that all transplant types analyzed can result in excellent
survival when applied to infants with SCID identiﬁed early,
before onset of infections, underscoring the critical impor-
tance of universal newborn screening for SCID. While
the use of RIC/MAC in non-MSD recipients led to im-
provements in some aspects of immune recovery, the risks
of adverse effects on development, neurocognition, and
fertility remain a concern, and illustrate the need for less
toxic regimens.5
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Background: Previous studies have demonstrated the
adverse impact of HLA mismatch on the outcome of mye-
loablative conditioning and unrelated donor allogeneic he-
matopoietic cell transplantation (HCT). These have had
limited power in certain sub-groups, and do not reﬂect
changes in HCT utilization and technology.
Methods: Included were adult and pediatric patients who
had undergone ﬁrst myeloablative unrelated bone marrow
or peripheral blood HCT for AML, ALL, CML, or MDS between
1999 and 2011. Patient and donor had high resolution typing
for HLA-A, B, C, DRB1, DQB1, and DPB1. Study outcomes
included overall survival (OS), disease-free survival (DFS),
treatment-related mortality (TRM), malignancy relapse,
